US20170290787A1 - Organic Compounds - Google Patents

Organic Compounds Download PDF

Info

Publication number
US20170290787A1
US20170290787A1 US15/634,579 US201715634579A US2017290787A1 US 20170290787 A1 US20170290787 A1 US 20170290787A1 US 201715634579 A US201715634579 A US 201715634579A US 2017290787 A1 US2017290787 A1 US 2017290787A1
Authority
US
United States
Prior art keywords
composition according
mannitol
alkyl
receptor agonist
s1p receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/634,579
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Colleen Ruegger
Alan Edward Royce
Masaki Sasaki
Tokuhiro Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Mitsubishi Pharma Corp
Mitsubishi Tanabe Pharma Corp
Original Assignee
Novartis AG
Mitsubishi Pharma Corp
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US46121503P priority Critical
Priority to PCT/EP2004/003656 priority patent/WO2004089341A1/en
Priority to US10/552,005 priority patent/US20060275357A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20170290787(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US12/191,098 priority patent/US20090203798A1/en
Priority to US12/987,726 priority patent/US20110105620A1/en
Priority to US13/721,278 priority patent/US20130108675A1/en
Priority to US14/285,808 priority patent/US20140255497A1/en
Application filed by Novartis AG, Mitsubishi Pharma Corp, Mitsubishi Tanabe Pharma Corp filed Critical Novartis AG
Priority to US15/634,579 priority patent/US20170290787A1/en
Assigned to NOVARTIS AG, MITSUBISHI PHARMA CORPORATION reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROYCE, ALAN EDWARD, RUEGGER, COLLEEN, PUDIPEDDI, MADHUSUDHAN, OOMURA, TOMOYUKI, TAMURA, TOKUHIRO, SASAKI, MASAKI
Publication of US20170290787A1 publication Critical patent/US20170290787A1/en
Application status is Abandoned legal-status Critical

Links